



Pharmaids Pharmaceuticals Limited

PPL/BSE/Q3/114/16-17

Date: 14.02.2016

To
The Corporate Relation Department
The Bombay Stock Exchange Ltd.
Floor 25, P J Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

**Sub:- Submission of Auditors Limited Review Report -un-Audited
Result for the 3rd Quarter ended 31st December, 2016 - Reg.**

Ref:- Scrip Code 524572. Compliance of Clause 41 of the Listing Agreement

Herewith we are enclosing the Auditors Limited Review Report issued on the Financials for the 3rd Quarter ended 31st December, 2016 - Reg.

This is for your information & records in compliance of clause 41 of Listing Agreement.

Kindly acknowledge the receipt.

Thanking you

For Pharmaids Pharmaceuticals Limited

Compliance Officer
Encl :- As above

Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

EXTRACT OF STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31ST DECEMBER, 2016

(Amt in lakhs)

S. No	Particulars	3 months ended	9 months ended	3 months ended
		31.12.2016	31.12.2016	31.12.2015
		un-Audited		
1	Total Income from Operations	29.08	94.46	52.75
2	Net Profit/(Loss) from Ordinary activities after tax	(2.18)	(8.83)	(22.22)
3	Net Profit/(Loss) for the period after tax (after Extraordinary items)	(2.18)	(8.83)	(22.22)
4	Equity Share Capital (of Rs. 10/- each)	336.31	336.31	336.31
5	Reserve excluding Revaluation Reserve as shown in the Balance Sheet of previous year	9.94	9.94	9.94
6	Earnings Per Share (before extra- ordinary items - not annualised)			
	a) Basic	(0.06)	(0.26)	(0.66)
	b) Diluted	(0.06)	(0.26)	(0.66)
7	Earnings Per Share (after extra- ordinary items - not annualised)			
	a) Basic	(0.06)	(0.26)	(0.66)
	b) Diluted	(0.06)	(0.26)	(0.66)

Notes:

1)The above is an extract of the detailed format of Quarterly financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the un-audited results are available on the stock Exchange website (www.nseindia.com and www.bseindia.com) and on the Company's website (www.pharmaids.com)

2)Company has entered into agreement for sale of assets situated at Survey No.533, (v) Kondamadugu, (M) Bibinagar, District Nalgonda, Telangana. The same is being materialise in the next quarter, hence the impact will be considered in next Quarter.

For PHARMAIDS PHARMACEUTICALS LIMITED

Ghisulal Jain

Dr. Ghisulal Jain
Managing Director

PLACE : Hyderabad
DATE : 14-02-2017



RAKESH S JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

14-6-191, Nagar Khana, Begum Bazar,
HYDERABAD - 500 012. (A.P.) INDIA

E-mail : rsjainassociates@rediffmail.com
Fax : 040-24617420

B. Ramesh Kumar (Mob) : +91-9849025641

Date : 14/02/2017

LIMITED REVIEW REPORT

To
The Board of Directors,
M/s Pharmaids Pharmaceuticals Limited,
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of **M/s Pharmaids Pharmaceuticals Limited** for the Quarter ended 31st December, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **RAKESH S. JAIN AND ASSOCIATES**
Chartered Accountants
Firm Registration No. 010129S